Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
15,213 questions in 2,394 reviews
current versionsNo studies 15,213 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Recombinant human adenovirus‐p53 and 5‐fluorouracil (rAd‐p53/5‐Fu) plus transarterial chemoembolisation vs transarterial chemoembolisation Adverse events considered non‐serious (number of events) · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | no estimate extracted | NR | No studies |
E1B‐deleted (dl1520) adenovirus vs percutaneous ethanol injection Overall survival · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | no estimate extracted | NR | No studies |
E1B‐deleted (dl1520) adenovirus vs percutaneous ethanol injection Proportion of people with ≥ 1 serious adverse events · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | no estimate extracted | NR | No studies |
E1B‐deleted (dl1520) adenovirus vs percutaneous ethanol injection Health‐related quality of life · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | no estimate extracted | NR | No studies |
Adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver transplantation vs liver transplantation Proportion of people with ≥ 1 serious adverse events during treatment · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | no estimate extracted | NR | No studies |
Adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver transplantation vs liver transplantation Health‐related quality of life · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | no estimate extracted | NR | No studies |
Adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver transplantation vs liver transplantation Proportion of people with disease progression · participants with unresectable hepatocellular carcinoma Gene therapy for people with hepatocellular carcinoma (2024) · Cochrane | no estimate extracted | NR | No studies |
Medication or nutrition fall prevention interventions vs control: evidence from RCTs Rate of falls · community‐dwelling older adults ≥ 65 years of age Population‐based interventions for preventing falls and fall‐related injuries in older people (2024) · Cochrane | no estimate extracted | NR | No studies |
Multicomponent fall prevention interventions vs control: evidence from RCTs Adverse events · community‐dwelling older adults at least 60 years of age Population‐based interventions for preventing falls and fall‐related injuries in older people (2024) · Cochrane | no estimate extracted | NR | No studies |
Multicomponent fall prevention interventions vs control: evidence from RCTs Cost‐effectiveness (economic analysis) · community‐dwelling older adults at least 60 years of age Population‐based interventions for preventing falls and fall‐related injuries in older people (2024) · Cochrane | no estimate extracted | NR | No studies |
Multicomponent fall prevention interventions vs control: evidence from non‐randomised trials Number of people experiencing 1 or more falls resulting in hospital admission Measured using hospital records · community‐dwelling older adults at least 60 years of age Population‐based interventions for preventing falls and fall‐related injuries in older people (2024) · Cochrane | no estimate extracted | NR | No studies |
Medication or nutrition fall prevention interventions vs control: evidence from RCTs Number of fallers · community‐dwelling older adults ≥ 65 years of age Population‐based interventions for preventing falls and fall‐related injuries in older people (2024) · Cochrane | no estimate extracted | NR | No studies |
Multicomponent fall prevention interventions vs control: evidence from non‐randomised trials Adverse events · community‐dwelling older adults at least 60 years of age Population‐based interventions for preventing falls and fall‐related injuries in older people (2024) · Cochrane | no estimate extracted | NR | No studies |
Medication or nutrition fall prevention interventions vs control: evidence from RCTs Number of people experiencing 1 or more fall‐related injuries · community‐dwelling older adults ≥ 65 years of age Population‐based interventions for preventing falls and fall‐related injuries in older people (2024) · Cochrane | no estimate extracted | NR | No studies |
Medication or nutrition fall prevention interventions vs control: evidence from RCTs Number of people experiencing 1 or more fall‐related fractures · community‐dwelling older adults ≥ 65 years of age Population‐based interventions for preventing falls and fall‐related injuries in older people (2024) · Cochrane | no estimate extracted | NR | No studies |
Medication or nutrition fall prevention interventions vs control: evidence from RCTs Number of people who experienced 1 or more adverse events · community‐dwelling older adults ≥ 65 years of age Population‐based interventions for preventing falls and fall‐related injuries in older people (2024) · Cochrane | no estimate extracted | NR | No studies |
Medication or nutrition fall prevention interventions vs control: evidence from RCTs Economic analysis · community‐dwelling older adults ≥ 65 years of age Population‐based interventions for preventing falls and fall‐related injuries in older people (2024) · Cochrane | no estimate extracted | NR | No studies |
Shared decision‐making (all components) vs control Satisfaction with the decision‐making process · women aged 40 to 75 years at average to moderate risk of breast cancer Shared decision‐making for supporting women’s decisions about breast cancer screening (2024) · Cochrane | no estimate extracted | NR | No studies |
Some components of shared decision‐making, including clarification of values and preferences, vs control Adherence to the chosen option · women aged 38 to 71 years at average to moderate risk of breast cancer Shared decision‐making for supporting women’s decisions about breast cancer screening (2024) · Cochrane | no estimate extracted | NR | No studies |
Some components of shared decision‐making, including clarification of values and preferences, vs control Choice of an option aligned with each woman’s values and preferences · women aged 38 to 71 years at average to moderate risk of breast cancer Shared decision‐making for supporting women’s decisions about breast cancer screening (2024) · Cochrane | no estimate extracted | NR | No studies |
Some components of shared decision‐making, including clarification of values and preferences, vs control Woman's involvement · women aged 38 to 71 years at average to moderate risk of breast cancer Shared decision‐making for supporting women’s decisions about breast cancer screening (2024) · Cochrane | no estimate extracted | NR | No studies |
Studies focused only on enhanced communication, without clarification of values and preferences, vs control Satisfaction with the decision‐making process · women aged 40 to 75 years old at average to moderate risk of breast cancer Shared decision‐making for supporting women’s decisions about breast cancer screening (2024) · Cochrane | no estimate extracted | NR | No studies |
Studies focused only on enhanced communication, without clarification of values and preferences, vs control Adherence to the chosen option · women aged 40 to 75 years old at average to moderate risk of breast cancer Shared decision‐making for supporting women’s decisions about breast cancer screening (2024) · Cochrane | no estimate extracted | NR | No studies |
Studies focused only on enhanced communication, without clarification of values and preferences, vs control Choice of an option aligned with each woman’s values and preferences · women aged 40 to 75 years old at average to moderate risk of breast cancer Shared decision‐making for supporting women’s decisions about breast cancer screening (2024) · Cochrane | no estimate extracted | NR | No studies |
Shared decision‐making (all components) vs control Confidence in the decision made · women aged 40 to 75 years at average to moderate risk of breast cancer Shared decision‐making for supporting women’s decisions about breast cancer screening (2024) · Cochrane | no estimate extracted | NR | No studies |
Studies focused only on enhanced communication, without clarification of values and preferences, vs control Woman's involvement · women aged 40 to 75 years old at average to moderate risk of breast cancer Shared decision‐making for supporting women’s decisions about breast cancer screening (2024) · Cochrane | no estimate extracted | NR | No studies |
Shared decision‐making (all components) vs control Adherence to the chosen option · women aged 40 to 75 years at average to moderate risk of breast cancer Shared decision‐making for supporting women’s decisions about breast cancer screening (2024) · Cochrane | no estimate extracted | NR | No studies |
Shared decision‐making (all components) vs control Choice of an option aligned with each woman’s values and preferences · women aged 40 to 75 years at average to moderate risk of breast cancer Shared decision‐making for supporting women’s decisions about breast cancer screening (2024) · Cochrane | no estimate extracted | NR | No studies |
Shared decision‐making (all components) vs control Woman's involvement · women aged 40 to 75 years at average to moderate risk of breast cancer Shared decision‐making for supporting women’s decisions about breast cancer screening (2024) · Cochrane | no estimate extracted | NR | No studies |
Shared decision‐making (all components) vs control Mental health outcomes · women aged 40 to 75 years at average to moderate risk of breast cancer Shared decision‐making for supporting women’s decisions about breast cancer screening (2024) · Cochrane | no estimate extracted | NR | No studies |
Some components of shared decision‐making, including clarification of values and preferences, vs control Satisfaction with the decision‐making process · women aged 38 to 71 years at average to moderate risk of breast cancer Shared decision‐making for supporting women’s decisions about breast cancer screening (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Vitamin B12 supplementation vs placebo/no vitamin B12 supplementation Neural tube defects ‐ not reported · pregnant women Vitamin B12 supplementation during pregnancy for maternal and child health outcomes (2024) · Cochrane | no estimate extracted | NR | No studies |
Intrauterine infusion of autologous platelet‐rich plasma vs intrauterine infusion of granulocyte colony‐stimulating factor Adverse events · women undergoing assisted reproduction Autologous platelet‐rich plasma for assisted reproduction (2024) · Cochrane | no estimate extracted | NR | No studies |
Intraovarian injection of autologous platelet‐rich plasma vs no intervention Miscarriage · women undergoing assisted reproduction Autologous platelet‐rich plasma for assisted reproduction (2024) · Cochrane | no estimate extracted | NR | No studies |
Intraovarian injection of autologous platelet‐rich plasma vs no intervention Adverse events · women undergoing assisted reproduction Autologous platelet‐rich plasma for assisted reproduction (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Psychosocial intervention vs control Functioning at · promoting the mental health of people living in LMICs affected by humanitarian crises (adults) Psychological and social interventions for the promotion of mental health in people living in low‐ and… (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Psychosocial intervention vs control Prosocial behaviour at study endpoint ‐ not measured · promoting the mental health of people living in LMICs affected by humanitarian crises (adults) Psychological and social interventions for the promotion of mental health in people living in low‐ and… (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Psychosocial intervention vs control Prosocial behaviour at · promoting the mental health of people living in LMICs affected by humanitarian crises (adults) Psychological and social interventions for the promotion of mental health in people living in low‐ and… (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Psychosocial intervention vs control Functioning at study endpoint ‐ not measured · promoting the mental health of people living in LMICs affected by humanitarian crises (adults) Psychological and social interventions for the promotion of mental health in people living in low‐ and… (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: plantar‐incision neurectomy (PN) vs dorsal‐incision neurectomy (DN) Pain: VAS(0 to 100; lower score indicates less pain) · Morton's neuroma Treatments for Morton's neuroma (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: plantar‐incision neurectomy (PN) vs dorsal‐incision neurectomy (DN) Function: restrictions in daily activities (4‐item Likert scale) · Morton's neuroma Treatments for Morton's neuroma (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: plantar‐incision neurectomy (PN) vs dorsal‐incision neurectomy (DN) HRQoL · Morton's neuroma Treatments for Morton's neuroma (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: ultrasound‐guided injection of corticosteroid and local anaesthetic (UG CS+LA) vs non‐ultrasound‐guided injection of corticosteroid and local anaesthetic (NUG CS+LA) HRQoL · Morton's neuroma Treatments for Morton's neuroma (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Change in claudication distance from baseline (m) · people with intermittent claudication Mobile health technologies to improve walking distance in people with intermittent claudication (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Amputation‐free survival · people with intermittent claudication Mobile health technologies to improve walking distance in people with intermittent claudication (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Revascularisation‐free survival · people with intermittent claudication Mobile health technologies to improve walking distance in people with intermittent claudication (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Major adverse limb events (MALE) · people with intermittent claudication Mobile health technologies to improve walking distance in people with intermittent claudication (2024) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Above‐ankle amputation · people with intermittent claudication Mobile health technologies to improve walking distance in people with intermittent claudication (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Continuous infusion of intravenous loop diuretics vs bolus injection of intravenous loop diuretics Cardiovascular mortality ‐ not measured · adults (aged greater than 18 years) with acute heart failure Continuous infusion versus bolus injection of loop diuretics for acute heart failure (2024) · Cochrane | no estimate extracted | NR | No studies |
Zinc vs placebo Risk of serious adverse events, including those that may be complications of the common cold · adults and children with colds and/or upper respiratory infections Zinc for prevention and treatment of the common cold (2024) · Cochrane | no estimate extracted | NR | No studies |